MADISON, Wis.--(BUSINESS WIRE)--NeuroPointDX, a division of Stemina Biomarker Discovery, today announced the appointment of two new board members with extensive experience in the development and commercialization of new molecular diagnostic tests. Barbara Handelin, PhD was founding Director of the DNA Diagnostics Lab at Integrated Genetics (acquired by LabCorp @ $925M), and Tony Shuber was Chief Technology Officer and cofounder of Exact Science Corporation and Predictive Biosciences. The appointments signal NeuroPointDX’s expansion of its pipeline of diagnostic and precision medicine offerings in autism and other complex brain disorders including anxiety and depression.
“Barbara and Tony’s vision for innovation in diagnostics will be key to expanding NeuroPointDX’s portfolio of tests related to autism and other neurological disorders. The tremendous talent and vision of these two veteran diagnostics executives will serve our company well as we continue our novel approach to diagnosing complex brain disorders through the application of world-class metabolomics,” said Chief Executive Officer Elizabeth Donley.
Dr. Handelin is a veteran molecular medical geneticist who, in addition to her role at Integrated Genetics, co-founded several other companies including Genovo and Kenna Technologies. She is also a cofounder of the non-profit BioPontis Alliance for Rare Diseases. Today she is CEO of Audacity Therapeutics, Public Benefit Corporation, and Audacity R4 Medicines Fund.
Tony Shuber, who led the diagnostics innovations at Integrated Genetics, is a serial entrepreneur with 25 years of experience in diagnostics and applied genomics. Shuber holds more than 100 patents for diagnostic and precision medicine platform technologies. He is currently the President and CTO of Genetics Research, LLC, and Stitch Bio.
“It’s a rare moment when a team of innovators and committed businesspeople have the opportunity to change medicine -- dramatically. The delineation of a biological profile for a complex behavioral disorder like autism spectrum disorder, as the team at NeuroPointDX has achieved, is such an opportunity,” commented Handelin. “I am pleased to be part of the company at such a pivotal point.”
NeuroPointDX, is transforming diagnosis and more precise treatment of neurological disorders using its proprietary metabolomics platform technology to subtype difficult to diagnose and treat neurological disorders. The company’s first program in autism spectrum disorders has resulted in the reproducible identification of unique metabolic signatures (called metabotypes) that enable the identification of more than 50% of children at risk of an autism diagnosis as early as age 18 months. NeuroPointDX will begin expanding its product pipeline into anxiety and depression this fall beginning with a study in bipolar disorder with the University of Michigan Medical School, using the same proprietary metabolism-based approach to subtyping complex neurological disorders.
NeuroPointDX, a business unit of Stemina Biomarker Discovery, is bringing a precision medicine approach to the diagnosis and treatment of neurological disorders through the application of world-class metabolomics. The company’s initial focus is autism spectrum disorder (ASD). NeuroPointDX has developed and is commercializing testing panels to aid in the early diagnosis of ASD through its CLIA-certified and CAP accredited laboratory. For more information, please visit our website at https://neuropointdx.com/.